miRNA-mediated regulation of LPS tolerance

Columbia University Health Sciences, New York NY

Investigators

Linked publications & trials

Abstract

? DESCRIPTION (provided by applicant): The inflammatory response results from a carefully balanced pattern of gene expression that is designed to control microbial infection, while limiting damaging inflammation. Excessive production of inflammatory cytokines contributes to the progression of the infection-triggered systemic inflammatory condition, sepsis. In what may be a protective response against this deleterious outcome, macrophages become tolerant to prolonged treatment with pro-inflammatory agents such as lipopolysaccharide (LPS). Tolerant macrophages reduce production of pro-inflammatory cytokines in favor of anti- inflammatory and anti-microbial genes upon re-stimulation. However, the molecular basis of this phenomenon is not clearly defined. Diverse mechanisms can lead to the selective gene expression seen during processes such as the induction of tolerance. MicroRNAs (miRNAs), in particular, have emerged as important post-transcriptional regulators of selective gene expression. Thus far, no miRNA has been found to selectively affect transcription in a way that recapitulates the gene expression changes noted during LPS tolerance. However, we have identified a number of miRNA species that are expressed in macrophages after prolonged exposure to LPS treatment and which appear to selectively modulate the expression of inflammation-related genes. miR-222 was the most highly expressed of the miRNAs identified in our screen, and our preliminary results suggest that miR-222 targets the Brg1 subunit of the SWI/SNF remodeling complex in macrophages. This targeting leads to attenuated production of a subset of inflammatory cytokines; however, it leaves TLR4 signaling intact. Given the kinetics of miR-222 expression, and the fact that the newly defined miR-222 target, Brg1, has been shown to mediate chromatin remodeling at selective promoters during LPS tolerization, we hypothesize that miR-222 may be a bona fide regulator of tolerance. We plan to utilize genomic analysis and a novel genetic model to validate the role of miR-222 as a regulator of tolerance. This project has exciting implications for the design of therapeutics to acutely induce tolerance and combat inflammation during sepsis progression.